Private Placement (Form 8-K)

On June 16, 2025, PetVivo Holdings, Inc., including its wholly-owned subsidiary PetVivo Animal Health, Inc., (collectively the "Company", "we" and "us") received Two Hundred Thousand Dollars ($200,000) pursuant to the partial exercise of a purchase option ("Purchase Option") granted to the investor as part of an offering to receive Five Million Dollars ($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock ("Shares") (the "Offering"); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock. The Company has previously received an aggregate total of Eight Hundred Thousand Dollars ($800,000) of the Offering prior to the current Purchase Option exercise. An additional Four Million Dollars ($4,000,000) of the Purchase Option remains for exercise at the investor's discretion pursuant to the terms and conditions of the subscription agreement of the Offering ("Subscription Agreement"). It is anticipated the remaining Four Million Dollars ($4,000,000) of the Purchase Option will be received by the Company on or before June 26, 2025.

The Offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended ("Securities Act"). The investor entered into the Subscription Agreement with the Company and represented in writing that he, she, or it is an "accredited investor" (as such term is defined in Rule 501(a) of Regulation D under the Securities Act) and acquired the securities for his, her or its own account for investment purposes and any subsequent transfer or sales of these securities will be in accordance with the Securities Act or exempt from registration under the Securities Act. The shares of Series B Preferred Stock will be "restricted securities" under Rule 144 of the Securities Act, and certificates representing the foregoing will bear a Rule 144 restrictive legend.

The form of Subscription Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K, respectively, and the description in this Current Report on Form 8-K of terms of Subscription Agreement are qualified in their entirety by reference to such exhibits.

In connection with the Offering, on March 26, 2025, the Company filed a Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (the "Certificate of Designation") with the Secretary of State of the State of Nevada designating 5,000,000 shares of the Company's Preferred Stock, $0.001 par value per share, as "Series B Convertible Preferred Stock," and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Series B Preferred Stock. An Amendment to the Certificate of Designation was filed with the Secretary of State of Nevada on March 31, 2025, which provided clarifications to the Company Call Option. A copy of the full text of the Certificate of Designation is attached hereto as Exhibit 3.1 to this Current Report on Form 8-K.